Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Intravitreal Moxalactam

Intravitreal Moxalactam Abstract To the Editor. —We read with interest the article by Fett et al1 regarding the injection of moxalactam into rabbit vitreous. Their findings that doses of 1.25 mg injected into the vitreous produced no toxic damage to the retina are similar to our data in which we demonstrated that doses of 2 mg or less were not associated with any demonstrable retinal toxicity. Our article,2 which was published in 1982, is the only other study to date which has examined the use of moxalactam in the eye. In addition to the toxicity studies, we examined the in vivo effectiveness of moxalactam in experimental staphylococcal endophthalmitis. Nine of nine eyes inoculated with Staphylococcus aureus and injected with 2 mg of moxalactam were sterile at the end of the treatment period. Focal retinal irregularities were observed in three eyes. These irregularities were presumably related to the injection technique. We also References 1. Fett DR, Silverman CA, Yoshizumi MO: Moxalactam retinal toxicity . Arch Ophthalmol 1984;102:435-438.Crossref 2. Leeds H, Peyman GA, House B: Moxalactam (Moxam) in the treatment of experimental staphylococcal endophthalmitis . Ophthalmic Surg 1982;13:653-656. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Ophthalmology American Medical Association

Loading next page...
 
/lp/american-medical-association/intravitreal-moxalactam-dMgv2F5sPg

References (2)

Publisher
American Medical Association
Copyright
Copyright © 1984 American Medical Association. All Rights Reserved.
ISSN
0003-9950
eISSN
1538-3687
DOI
10.1001/archopht.1984.01040031027009
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. —We read with interest the article by Fett et al1 regarding the injection of moxalactam into rabbit vitreous. Their findings that doses of 1.25 mg injected into the vitreous produced no toxic damage to the retina are similar to our data in which we demonstrated that doses of 2 mg or less were not associated with any demonstrable retinal toxicity. Our article,2 which was published in 1982, is the only other study to date which has examined the use of moxalactam in the eye. In addition to the toxicity studies, we examined the in vivo effectiveness of moxalactam in experimental staphylococcal endophthalmitis. Nine of nine eyes inoculated with Staphylococcus aureus and injected with 2 mg of moxalactam were sterile at the end of the treatment period. Focal retinal irregularities were observed in three eyes. These irregularities were presumably related to the injection technique. We also References 1. Fett DR, Silverman CA, Yoshizumi MO: Moxalactam retinal toxicity . Arch Ophthalmol 1984;102:435-438.Crossref 2. Leeds H, Peyman GA, House B: Moxalactam (Moxam) in the treatment of experimental staphylococcal endophthalmitis . Ophthalmic Surg 1982;13:653-656.

Journal

Archives of OphthalmologyAmerican Medical Association

Published: Sep 1, 1984

There are no references for this article.